Adverse Event Clinical Research, published by HL7 International / Biomedical Research and Regulation. This guide is not an authorized publication; it is the continuous build for version 1.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-ae-research-ig/ and changes regularly. See the Directory of published versions
Contents:
This page provides a list of the FHIR artifacts defined as part of this implementation guide.
These define constraints on FHIR resources for systems conforming to this implementation guide.
Adverse Event Clinical Research |
Foundational profile of AdverseEvent for Clinical Research communications. |
These define constraints on FHIR data types for systems conforming to this implementation guide.
Adverse Event Grade |
For cancer related trials, severity is represented as a grade. Describes the grade of the adverse event, in relation to the subject not the resulting condition. In the context of clinical research, it is the investigator’s assessment of severity, in oncology related trials this is reported as grade. |
Adverse Event Severity |
Describes the severity of the adverse event, in relation to the subject not the resulting condition. In the context of clinical research, it is the investigator’s assessment of severity. |
Adverse event caused subject to discontinue the study |
Indicates if the subject discontinued the study due to the adverse event. |
Criteria reviewed in determining serious adverse event |
Element to capture the presence or absence of specific factors (criteria) associated with serious adverse events. |
These are example instances that show what data produced and consumed by systems conforming with this implementation guide might look like.
AdverseEventFromProcedureNotStudyDrug |
Adverse event from procedure, not study drug |
ClinicalTrialSignificantAdverseEvent |
example |
NonSeriousAdverseEventResearchStudyMed |
Non-Serious Adverse Event Research Study Medication Example |
Patient reported AE during research study |
Patient report of Adverse Event, example of data that would be on MedWatch form as reported by Patient |
SeriousAdverseEventResearchStudy |
Serious Adverse Event Research Study Medication Example |
adverse-event-compass-ex1 |
Grade 1 ALT |
adverse-event-compass-ex1a |
Grade 3 ALT |
adverse-event-compass-ex1b |
ALT back to grade 1 and resolved |
adverse-event-compass-ex2 |
Grade 1 Nausea/vomiting // both are AEs, which to use or make them separate? |
adverse-event-device-death |
Device suspected entity |
These are resources that are used within this implementation guide that do not fit into one of the other categories.
AEHeadache |
Headache |
AEHepaticFailure |
The fifth subject enrolled in the trial develops severe hepatic failure complicated by encephalopathy one month after starting the study. The study sponsors determined that is an unanticipated problem that must be reported because although the risk of mild liver injury was foreseen, severe liver injury resulting in hepatic failure was unexpected in severity; possibly related to participation in the research; and serious. |
AEHepaticFailurecomplication |
The fifth subject enrolled in the trial develops severe hepatic failure complicated by encephalopathy one month after starting the study. The study sponsors determined that is an unanticipated problem that must be reported because although the risk of mild liver injury was foreseen, severe liver injury resulting in hepatic failure was unexpected in severity; possibly related to participation in the research; and serious. |
AEModeratehives |
Moderate hives |
Breast Cancer Trial |
Breast Cancer clinical trial example |
ClinicalTrialSubject5 |
Clinical Trial subject number 5. Acute Hepatic Failure. |
Device - Infuser that exploded |
Device - Infuser that exploded |
Example patient SLP |
Patient enrolled in ACME study, taking Study Medication WBY 10 mg orally daily every morning for moderate asthma |
GIBleed |
Gastrointestinal (GI) bleed |
Janet Blood Pressure Observation |
Janet Blood Pressure Observation |
Janet Patient |
Patient Janet, 64-year old woman on clinical trial |
Janet Tylenol PM med |
Self reported Janet Tylenol PM med |
Janet allergy med |
Self reported Janet allergy med |
Janet pill for water retention med not known |
Self reported Janet pill for water retention med not known |
Janet weight Observation |
Janet weight observation |
Medication Administration for bresentrik |
Study medication info Medication Administration for bresentrik |
Medication Administration of Med0301 |
Medication administration example |
Medication Request for bresentrik |
Study medication info Medication Request for bresentrik |
Medication Request for discontinued clinical trial medication 0301 |
Study medication info Medication Request for clinical trial medication 0301 - discontinued |
Medication Request for discontinued clinical trial medication ABC |
Study medication info Medication Request for clinical trial medication ABC - discontinued |
Medication is bresentrik |
Study medication, bresentrik |
Patient MOUMIC |
Patient MOUMIC on Research Study DISNEY |
Problem |
Patient reported AE problem |
Serious Adverse Event |
SAE Patient SCHJO on Research Study XYZ, Study ID XYZ-123, Subject number XYZ-123-002. |
clinical-trial-acme-procedure |
Clinical trial ACME protocol-prescribed procedure of a Lung CT Scan, with contrast dye |
clinical-trial-acme-subject |
Clinical trial ACME research subject |
clinical-trial-example-compass |
Alliance COMPASS Protocol A011801 |
clinical-trial-example-subject |
Alliance COMPASS trial research subject |
clinical-trial-example-subject1 |
Alliance COMPASS trial research subject |
medication-administration-contrast-dye |
Example medication administration for contrast dye |
medication-administration-forhives |
Example medication administration for hives |
medication-administration-kadcyla |
Example showing clinical trial medication administration Kadcyla |
medication-administration-kadcyla-reduced |
Example reduced dose of clinical trial medication administration Kadcyla |
medication-administration-kadcyla1 |
Example showing clinical trial medication administration Kadcyla |
medication-administration-tucatinib |
Example showing clinical trial medication administration Tucatinib |
medication-administration-tucatinib-reduced |
Example reduced does of clinical trial medication administration Tucatinib |
medication-administration-tylenol |
Example of Tylenol |
medication-contrast-dye |
Example contrast dye medication |
medication-forhives |
Example medication for hives |
medication-request-example-kadcyla |
Example showing clinical trial medication Kadcyla |
medication-request-example-kadcyla1 |
Example showing clinical trial medication Kadcyla |
medication-request-example-tucatinib |
Example showing clinical trial medication Tucatinib |
medication-request-example-zofran |
Example for medication Zofran |
medication-tylenol |
Example medication for Tylenol |
patient-example-kaitlyn-b |
Compass Trial example patient Kaitlyn |
patient-example-kaitlyn-b1 |
Compass Trial example patient Kaitlynn B1 |
practitioner-oncology-nurse-jane |
Example RN practitioner |
practitioner-owen-oncologist |
Example Oncologist |
procedure-upper-endoscopy |
Example Procedure Upper Endoscopy |
research-study-DISNEY |
Research Study DISNEY |
research-study-XYZ |
Research Study XYZ |
research-study-acme |
Research Study ACME |
resstudy-medication-WBY |
Example clinical trial medication WBY |
study-medication-ABC |
Example study medication ABC |
study-medication-MMD |
Example study medication MMD |
study-medication-administration-ABC |
Example for clinical trial medication ABC |
study-medication-administration-MMD |
Example for clinical trial medication MMD |
study-medication-administration-WBY |
Example for clinical trial medication WBY |